🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the effort against drug-resistant strains of the pathogen, according to researchers.

An International Challenge

Gonorrhoea infections are escalating globally, with figures suggesting more than 82 million new cases each year. Especially elevated rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the face of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices at this time.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, also received approval in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This authorization signifies a major breakthrough in the treatment of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Results and Worldwide Availability

According to data detailed in a major medical journal, zoliflodacin eradicated more than 90% of cases of the STI. This puts it on an similar efficacy with the typical regimen, which involves a dual-drug approach. The study included nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Doctors directly involved have expressed optimism. Having a single-dose, oral treatment of this kind is seen as a "revolutionary step" for public health efforts. This is deemed essential to reduce the burden of the disease for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.